Form D · Pharmaceuticals

Sparrow Pharmaceuticals, Inc.

Portland, OR · CIK 0001786949

Offering snapshot reported Jul 1, 2025 · SEC filing

Reported sold
$61.8M
Offering amount: $121M
Investors reported
17
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jun 20, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jul 1, 2025Initial$61,841,225No comparison17SEC filing
Apr 12, 2024Initial$10,000,000No comparison4SEC filing
Jan 13, 2021Initial$1,075,255No comparison15SEC filing
Jun 26, 2020Amendment$337,500$67,500vs Nov 15, 201910SEC filing
Nov 15, 2019Initial$270,000No comparison10SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-550457
Total offering amount and total amount sold include the conversion of $18,525,050.35 of outstanding convertible securities.

Source: Form D, filed Jul 1, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Robert Jacks Director, Executive
David Katz Executive
Nanna L?Neborg Director
Niall O'donnell Director
Jonathan Root Director
Zach Scheiner Director
Peter Thompson Director
Klaus Veitinger Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
1050 Southwest 6th Street Suite 1100
Portland, OR, 97204
Phone: 6174650328